The stock of Aralez Pharmaceuticals Inc (TSE:ARZ) is a huge mover today! About 20,690 shares traded hands. Aralez Pharmaceuticals Inc (TSE:ARZ) has declined 20.90% since March 10, 2016 and is downtrending. It has underperformed by 26.51% the S&P500.
The move comes after 6 months negative chart setup for the $393.82M company. It was reported on Oct, 17 by Barchart.com. We have $5.33 PT which if reached, will make TSE:ARZ worth $55.13 million less.
More notable recent Aralez Pharmaceuticals Inc (TSE:ARZ) news were published by: Investorplace.com which released: “Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal” on October 04, 2016, also Fool.com with their article: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” published on August 01, 2016, Fool.com published: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” on September 15, 2016. More interesting news about Aralez Pharmaceuticals Inc (TSE:ARZ) were released by: Marketwatch.com and their article: “/quotes/zigman/3870025/realtime” published on February 12, 2016 as well as Seekingalpha.com‘s news article titled: “Aralez Pharmaceuticals Inc.: Upcoming Catalysts Create Tremendous Upside” with publication date: August 18, 2016.
Aralez Pharmaceuticals Inc. is a Canada specialty pharmaceutical company. The company has a market cap of $393.82 million. The Firm focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. It currently has negative earnings. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.